Evaluation of the potential of Mycobacterium smegmatis as vaccine Candidate against tuberculosis by in silico and in vivo studies

VacciMonitor. 2010;19(1):20-26

 

Journal Homepage

Journal Title: VacciMonitor

ISSN: 1025-028X (Print); 1025-0298 (Online)

Publisher: Finlay Ediciones

Society/Institution: Cuban Society of Immunology, and Cuban Society of Pharmacology

LCC Subject Category: Medicine

Country of publisher: Cuba

Language of fulltext: Spanish; Castilian, English

Full-text formats available: PDF, HTML

 

AUTHORS

Le Thuy Nguyen Thi (Biotechnology Centre of Ho Chi Minh City, 176 Hai Ba Trung Street, Ho Chi Minh City, Vietnam)
Reinier Borrero Maura (Finlay Institute. Center for Vaccine Research & Production. Ave 27 No 19805, La Lisa, Havana City, AP16017 CP11600, Cuba)
Sonsire Férnandez (Finlay Institute. Center for Vaccine Research & Production. Ave 27 No 19805, La Lisa, Havana City, AP16017 CP11600, Cuba)
Giselle Reyes (Finlay Institute. Center for Vaccine Research & Production. Ave 27 No 19805, La Lisa, Havana City, AP16017 CP11600, Cuba)
José Luis Perez (Finlay Institute. Center for Vaccine Research & Production. Ave 27 No 19805, La Lisa, Havana City, AP16017 CP11600, Cuba)
Fátima Reyes (Finlay Institute. Center for Vaccine Research & Production. Ave 27 No 19805, La Lisa, Havana City, AP16017 CP11600, Cuba)
María de los Angeles García (Finlay Institute. Center for Vaccine Research & Production. Ave 27 No 19805, La Lisa, Havana City, AP16017 CP11600, Cuba)
Midrey Fariñas (Finlay Institute. Center for Vaccine Research & Production. Ave 27 No 19805, La Lisa, Havana City, AP16017 CP11600, Cuba)
Juan Francisco Infante (Finlay Institute. Center for Vaccine Research & Production. Ave 27 No 19805, La Lisa, Havana City, AP16017 CP11600, Cuba)
Yanely Tirado (Finlay Institute. Center for Vaccine Research & Production. Ave 27 No 19805, La Lisa, Havana City, AP16017 CP11600, Cuba)
Alina Puig (Finlay Institute. Center for Vaccine Research & Production. Ave 27 No 19805, La Lisa, Havana City, AP16017 CP11600, Cuba)
Gustavo Sierra (Finlay Institute. Center for Vaccine Research & Production. Ave 27 No 19805, La Lisa, Havana City, AP16017 CP11600, Cuba)
Nadine Álvarez (Finlay Institute. Center for Vaccine Research & Production. Ave 27 No 19805, La Lisa, Havana City, AP16017 CP11600, Cuba)
Juan Carlos Ramírez (Finlay Institute. Center for Vaccine Research & Production. Ave 27 No 19805, La Lisa, Havana City, AP16017 CP11600, Cuba)
María Elena Sarmiento (Finlay Institute. Center for Vaccine Research & Production. Ave 27 No 19805, La Lisa, Havana City, AP16017 CP11600, Cuba)
Mohd-Nor Norazmi (School of Health Sciences, Universiti Sains Malaysia, 16150 Kubang Kerian, Malaysia)
Armando Acosta (Finlay Institute. Center for Vaccine Research & Production. Ave 27 No 19805, La Lisa, Havana City, AP16017 CP11600, Cuba)

EDITORIAL INFORMATION

Double blind peer review

Editorial Board

Instructions for authors

Time From Submission to Publication: 16 weeks

 

Abstract | Full Text

In this study, we scanned multiple published databases of gene expression in vivo of M. tuberculosis at different phases of infection in animals and humans, to select 38 proteins that are highly expressed in the active, latent and reactivation phases. The selected proteins were predicted for T and B epitopes. For each proteins, the regions containing T and B epitopes were selected at the same time to look for identical epitopes on M. smegmatis based on sequence alignments. Preliminary studies of humoral immunogenicity and cross-reactivity with M. tuberculosis in mice using two M. smegmatis-derived experimental vaccines were carried out, demonstrating the immunogenicity of M. smegmatis proteoliposomes and the recognition of M. tuberculosis proteins by the sera of animals immunized with this vaccine candidate. The conjunction of in silico and in vivo studies suggested the potential for future evaluation of M. smegmatis as vaccine candidate against tuberculosis using different strategies